FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesChallenges of the Cell, Gene, CAR-T and Personalized Medicine Supply Chains
Topics: Cold Chain, Conference, Supply Chain
Video
Members
COVID-19’s Impact on the Supply Chain in Asia-Pacific
Topics: COVID-19, Supply Chain
Webinar
Free
Video on eTMF Requirements provided by Steve Jacobs, Chairman at Global BioPharm Solutions.
Topics: Pharma Industry, Strategic Planning
Video
Members